标题
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
作者
关键词
-
出版物
Cells
Volume 9, Issue 1, Pages 167
出版商
MDPI AG
发表日期
2020-01-10
DOI
10.3390/cells9010167
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients
- (2019) Ajay K. Nooka et al. CANCER
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
- (2019) Antonio Giovanni Solimando et al. Journal of Clinical Medicine
- CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies
- (2019) Fabio Morandi et al. Cells
- Blocking “don't eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth review
- (2018) Atlantis Russ et al. BLOOD REVIEWS
- Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome byEx Vivo–Expanded Autologous NK Cells
- (2018) Yufeng Wang et al. CLINICAL CANCER RESEARCH
- CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience
- (2018) Kristine A. Frerichs et al. Expert Review of Clinical Immunology
- Immunomodulatory effects of CD38-targeting antibodies
- (2018) Niels W.C.J. van de Donk IMMUNOLOGY LETTERS
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pathogenesis of bone disease in multiple myeloma: from bench to bedside
- (2018) Evangelos Terpos et al. Blood Cancer Journal
- CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
- (2018) Limo Chen et al. Cancer Discovery
- Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
- (2018) Aurelia Lamanuzzi et al. Oncotarget
- Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis
- (2018) Hanke L. Matlung et al. Cell Reports
- Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+
- (2018) F. Morandi et al. OncoImmunology
- Autophagy: A New Mechanism of Prosurvival and Drug Resistance in Multiple Myeloma
- (2018) V. Desantis et al. Translational Oncology
- CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
- (2018) Niels W.C.J. van de Donk et al. Frontiers in Immunology
- Functional insights into nucleotide-metabolizing ectoenzymes expressed by bone marrow-resident cells in patients with multiple myeloma
- (2018) A.L. Horenstein et al. IMMUNOLOGY LETTERS
- Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma–Enhanced Angiogenesis: A Novel Therapeutic Target?
- (2018) Ilaria Saltarella et al. NEOPLASIA
- Daratumumab for the treatment of multiple myeloma
- (2017) Cyrille Touzeau et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The role of the complement system in cancer
- (2017) Vahid Afshar-Kharghan JOURNAL OF CLINICAL INVESTIGATION
- Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’
- (2017) Matthew Ho Zhi Guang et al. LEUKEMIA & LYMPHOMA
- Fcγ Receptor Heterogeneity in Leukocyte Functional Responses
- (2017) Carlos Rosales Frontiers in Immunology
- The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy
- (2017) Sourav Paul et al. Frontiers in Immunology
- CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
- (2017) Peter E. van Bommel et al. OncoImmunology
- Multiple myeloma in the marrow: pathogenesis and treatments
- (2016) Heather Fairfield et al. Annals of the New York Academy of Sciences
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
- (2016) Saad Z. Usmani et al. BLOOD
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance
- (2016) S. J. de Haart et al. HAEMATOLOGICA
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
- (2016) Niels W. C. J. van de Donk et al. IMMUNOLOGICAL REVIEWS
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma
- (2016) Alberto L Horenstein et al. MOLECULAR MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD
- (2016) Saad Usmani et al. ONCOLOGIST
- Microenvironment drug resistance in multiple myeloma: emerging new players
- (2016) Lucia Di Marzo et al. Oncotarget
- Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance
- (2016) S. J. de Haart et al. HAEMATOLOGICA
- CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer
- (2015) T. A. Karakasheva et al. CANCER RESEARCH
- Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients
- (2015) M A Frassanito et al. LEUKEMIA
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
- (2015) H Jiang et al. LEUKEMIA
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
- (2015) Marije B Overdijk et al. mAbs
- NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model
- (2015) Alberto Horenstein et al. Cells
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- CD38 and bone marrow microenvironment
- (2014) Antonella Chillemi Frontiers in Bioscience-Landmark
- Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity
- (2014) S. Herter et al. JOURNAL OF IMMUNOLOGY
- Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice
- (2014) P Macor et al. LEUKEMIA
- Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
- (2014) Saskia Meyer et al. mAbs
- γδ T Cell-Mediated Antibody-Dependent Cellular Cytotoxicity with CD19 Antibodies Assessed by an Impedance-Based Label-Free Real-Time Cytotoxicity Assay
- (2014) Ursula Jördis Eva Seidel et al. Frontiers in Immunology
- HIF-1 of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target
- (2013) R. Ria et al. CLINICAL CANCER RESEARCH
- Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies
- (2013) M A Frassanito et al. LEUKEMIA
- Unknown
- (2013) Antonella Chillemi et al. MOLECULAR MEDICINE
- CD19+CD24hiCD38hi B Cells Maintain Regulatory T Cells While Limiting TH1 and TH17 Differentiation
- (2013) F. Flores-Borja et al. Science Translational Medicine
- A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes
- (2013) Alberto L Horenstein et al. OncoImmunology
- CD38 signals upregulate expression and functions of matrix metalloproteinase-9 in chronic lymphocytic leukemia cells
- (2012) T Vaisitti et al. LEUKEMIA
- Human NK cell lytic granules and regulation of their exocytosis
- (2012) Konrad Krzewski et al. Frontiers in Immunology
- Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
- (2011) W. Hu et al. CANCER RESEARCH
- Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells
- (2011) Tao You et al. Cellular & Molecular Immunology
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16+ NK cells as rapid producers of abundant IFN- on activation
- (2010) A. De Maria et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD47 Regulates Bone Mass and Tumor Metastasis to Bone
- (2009) O. Uluckan et al. CANCER RESEARCH
- Functions and molecular mechanisms of the CD47–SIRPα signalling pathway
- (2009) Takashi Matozaki et al. TRENDS IN CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search